Detalhe da pesquisa
1.
In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms.
Blood
; 143(23): 2414-2424, 2024 Jun 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38457657
2.
Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms.
Exp Hematol
; 132: 104178, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38340948
3.
Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms.
J Clin Invest
; 134(3)2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38060311
4.
Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice.
Exp Hematol
; 128: 48-66, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37611729
5.
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression.
Nat Cancer
; 4(1): 108-127, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36581736
6.
Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition.
Blood Adv
; 6(2): 611-623, 2022 01 25.
Artigo
Inglês
| MEDLINE | ID: mdl-34644371